Interleukin-2 receptor targeted therapy of ocular disease of HTLV-1-associated adult T-cell leukemia

Theresa A. Larson, Mengjun Hu, John Edward Janik, Robert B. Nussenblatt, John C. Morris, H. Nida Sen

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Purpose: To report two cases of patients with ocular manifestations of human T-cell lymphotropic virus type-1 (HTLV-1) associated adult T-cell leukemia/lymphoma (ATL) who were successfully treated with interleukin-2 receptor targeted therapies. Method: Case series. Results: Two patients with HTLV-1-associated ATL developed symptomatic scleritis. In the first case, conjunctival biopsy showed leukemic infiltration that was confirmed by T-cell receptor polymerase chain reaction (PCR) demonstrating a clonal rearrangement. As treatment for ATL, both cases received interleukin-2 receptor targeted therapy. In one patient, daclizumab, a monoclonal antibody directed against the alpha chain of the interleukin-2 (IL-2) receptor, was used. The second patient was treated with denileukin diftitox, an immunotoxin fusion protein that targets the IL-2 receptor. Improvement in scleritis was noted in both patients. Conclusion: Scleritis in patients with underlying HTLV-1-associated ATL is responsive to IL-2 receptor targeted therapies.

Original languageEnglish (US)
Pages (from-to)312-314
Number of pages3
JournalOcular Immunology and Inflammation
Volume20
Issue number4
DOIs
StatePublished - Aug 1 2012

Fingerprint

Adult T Cell Leukemia Lymphoma
Human T-lymphotropic virus 1
Eye Diseases
Interleukin-2 Receptors
Scleritis
T-Lymphocytes
Eye Manifestations
Therapeutics
Leukemic Infiltration
Interleukin-2 Receptor alpha Subunit
Immunotoxins
T-Cell Antigen Receptor
Monoclonal Antibodies
Biopsy
Polymerase Chain Reaction
Proteins

Keywords

  • Adult T-cell leukemia/lymphoma
  • Daclizumab
  • Denileukin diftitox
  • Human T-cell lymphotropic virus type-1
  • Scleritis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Ophthalmology

Cite this

Interleukin-2 receptor targeted therapy of ocular disease of HTLV-1-associated adult T-cell leukemia. / Larson, Theresa A.; Hu, Mengjun; Janik, John Edward; Nussenblatt, Robert B.; Morris, John C.; Sen, H. Nida.

In: Ocular Immunology and Inflammation, Vol. 20, No. 4, 01.08.2012, p. 312-314.

Research output: Contribution to journalArticle

Larson, Theresa A. ; Hu, Mengjun ; Janik, John Edward ; Nussenblatt, Robert B. ; Morris, John C. ; Sen, H. Nida. / Interleukin-2 receptor targeted therapy of ocular disease of HTLV-1-associated adult T-cell leukemia. In: Ocular Immunology and Inflammation. 2012 ; Vol. 20, No. 4. pp. 312-314.
@article{e9a197c654e24bb0995c2c22b0b727b9,
title = "Interleukin-2 receptor targeted therapy of ocular disease of HTLV-1-associated adult T-cell leukemia",
abstract = "Purpose: To report two cases of patients with ocular manifestations of human T-cell lymphotropic virus type-1 (HTLV-1) associated adult T-cell leukemia/lymphoma (ATL) who were successfully treated with interleukin-2 receptor targeted therapies. Method: Case series. Results: Two patients with HTLV-1-associated ATL developed symptomatic scleritis. In the first case, conjunctival biopsy showed leukemic infiltration that was confirmed by T-cell receptor polymerase chain reaction (PCR) demonstrating a clonal rearrangement. As treatment for ATL, both cases received interleukin-2 receptor targeted therapy. In one patient, daclizumab, a monoclonal antibody directed against the alpha chain of the interleukin-2 (IL-2) receptor, was used. The second patient was treated with denileukin diftitox, an immunotoxin fusion protein that targets the IL-2 receptor. Improvement in scleritis was noted in both patients. Conclusion: Scleritis in patients with underlying HTLV-1-associated ATL is responsive to IL-2 receptor targeted therapies.",
keywords = "Adult T-cell leukemia/lymphoma, Daclizumab, Denileukin diftitox, Human T-cell lymphotropic virus type-1, Scleritis",
author = "Larson, {Theresa A.} and Mengjun Hu and Janik, {John Edward} and Nussenblatt, {Robert B.} and Morris, {John C.} and Sen, {H. Nida}",
year = "2012",
month = "8",
day = "1",
doi = "10.3109/09273948.2012.689071",
language = "English (US)",
volume = "20",
pages = "312--314",
journal = "Ocular Immunology and Inflammation",
issn = "0927-3948",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Interleukin-2 receptor targeted therapy of ocular disease of HTLV-1-associated adult T-cell leukemia

AU - Larson, Theresa A.

AU - Hu, Mengjun

AU - Janik, John Edward

AU - Nussenblatt, Robert B.

AU - Morris, John C.

AU - Sen, H. Nida

PY - 2012/8/1

Y1 - 2012/8/1

N2 - Purpose: To report two cases of patients with ocular manifestations of human T-cell lymphotropic virus type-1 (HTLV-1) associated adult T-cell leukemia/lymphoma (ATL) who were successfully treated with interleukin-2 receptor targeted therapies. Method: Case series. Results: Two patients with HTLV-1-associated ATL developed symptomatic scleritis. In the first case, conjunctival biopsy showed leukemic infiltration that was confirmed by T-cell receptor polymerase chain reaction (PCR) demonstrating a clonal rearrangement. As treatment for ATL, both cases received interleukin-2 receptor targeted therapy. In one patient, daclizumab, a monoclonal antibody directed against the alpha chain of the interleukin-2 (IL-2) receptor, was used. The second patient was treated with denileukin diftitox, an immunotoxin fusion protein that targets the IL-2 receptor. Improvement in scleritis was noted in both patients. Conclusion: Scleritis in patients with underlying HTLV-1-associated ATL is responsive to IL-2 receptor targeted therapies.

AB - Purpose: To report two cases of patients with ocular manifestations of human T-cell lymphotropic virus type-1 (HTLV-1) associated adult T-cell leukemia/lymphoma (ATL) who were successfully treated with interleukin-2 receptor targeted therapies. Method: Case series. Results: Two patients with HTLV-1-associated ATL developed symptomatic scleritis. In the first case, conjunctival biopsy showed leukemic infiltration that was confirmed by T-cell receptor polymerase chain reaction (PCR) demonstrating a clonal rearrangement. As treatment for ATL, both cases received interleukin-2 receptor targeted therapy. In one patient, daclizumab, a monoclonal antibody directed against the alpha chain of the interleukin-2 (IL-2) receptor, was used. The second patient was treated with denileukin diftitox, an immunotoxin fusion protein that targets the IL-2 receptor. Improvement in scleritis was noted in both patients. Conclusion: Scleritis in patients with underlying HTLV-1-associated ATL is responsive to IL-2 receptor targeted therapies.

KW - Adult T-cell leukemia/lymphoma

KW - Daclizumab

KW - Denileukin diftitox

KW - Human T-cell lymphotropic virus type-1

KW - Scleritis

UR - http://www.scopus.com/inward/record.url?scp=84864331957&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864331957&partnerID=8YFLogxK

U2 - 10.3109/09273948.2012.689071

DO - 10.3109/09273948.2012.689071

M3 - Article

C2 - 22642512

AN - SCOPUS:84864331957

VL - 20

SP - 312

EP - 314

JO - Ocular Immunology and Inflammation

JF - Ocular Immunology and Inflammation

SN - 0927-3948

IS - 4

ER -